AIM: To test the hypothesis that inhaled nitric oxide therapy can decrease the incidence of bronchopulmonary dysplasia and death in preterm infants with severe respiratory distress syndrome; to evaluate the possible predictive factors for the response to inhaled nitric oxide therapy. METHODS:Preterm infants (less than 30 weeks' gestation) were randomized to receive during the first week of life inhaled nitric oxide, or nothing, if they presented severe respiratory distress syndrome. Then, the treated infants were classified as non responders and responders. RESULTS:Twenty infants were enrolled in theinhaled nitric oxide therapygroup and 20 in the control group. Bronchopulmonary dysplasia and death were less frequent in the inhaled nitric oxide group than in the control group (50 vs. 90%, p=0.016). Moreover, nitric oxide treatment was found to decrease as independent factor the combined incidence of death and BPD (OR=0.111; 95% C.I. 0.02-0.610). A birth weight lower than 750 grams had a significant predictive value for the failure of responding to inhaled nitric oxide therapy (OR 12; 95% C.I. 1.3-13.3). CONCLUSION:Inhaled nitric oxide decreases the incidence of bronchopulmonary dysplasia and death in preterm infants with severe respiratory distress syndrome. Birth weight may influence the effectiveness of inhaled nitric oxide therapy in promoting oxygenation improvement in preterm infants.
RCT Entities:
AIM: To test the hypothesis that inhaled nitric oxide therapy can decrease the incidence of bronchopulmonary dysplasia and death in preterm infants with severe respiratory distress syndrome; to evaluate the possible predictive factors for the response to inhaled nitric oxide therapy. METHODS: Preterm infants (less than 30 weeks' gestation) were randomized to receive during the first week of life inhaled nitric oxide, or nothing, if they presented severe respiratory distress syndrome. Then, the treated infants were classified as non responders and responders. RESULTS: Twenty infants were enrolled in the inhaled nitric oxide therapy group and 20 in the control group. Bronchopulmonary dysplasia and death were less frequent in the inhaled nitric oxide group than in the control group (50 vs. 90%, p=0.016). Moreover, nitric oxide treatment was found to decrease as independent factor the combined incidence of death and BPD (OR=0.111; 95% C.I. 0.02-0.610). A birth weight lower than 750 grams had a significant predictive value for the failure of responding to inhaled nitric oxide therapy (OR 12; 95% C.I. 1.3-13.3). CONCLUSION: Inhaled nitric oxide decreases the incidence of bronchopulmonary dysplasia and death in preterm infants with severe respiratory distress syndrome. Birth weight may influence the effectiveness of inhaled nitric oxide therapy in promoting oxygenation improvement in preterm infants.
Authors: Lisa M Askie; Roberta A Ballard; Gary R Cutter; Carlo Dani; Diana Elbourne; David Field; Jean-Michel Hascoet; Anna Maria Hibbs; John P Kinsella; Jean-Christophe Mercier; Wade Rich; Michael D Schreiber; Pimol Srisuparp Wongsiridej; Nim V Subhedar; Krisa P Van Meurs; Merryn Voysey; Keith Barrington; Richard A Ehrenkranz; Neil N Finer Journal: Pediatrics Date: 2011-09-19 Impact factor: 7.124
Authors: Regan E Giesinger; Kiran More; Jodie Odame; Amish Jain; Robert P Jankov; Patrick J McNamara Journal: Pediatr Res Date: 2017-10-04 Impact factor: 3.756
Authors: Kevin R Ellsworth; Marc A Ellsworth; Amy L Weaver; Kristin C Mara; Reese H Clark; William A Carey Journal: JAMA Pediatr Date: 2018-07-02 Impact factor: 16.193
Authors: Lisa M Askie; Roberta A Ballard; Gary Cutter; Carlo Dani; Diana Elbourne; David Field; Jean-Michel Hascoet; Anna Maria Hibbs; John P Kinsella; Jean-Christophe Mercier; Wade Rich; Michael D Schreiber; Pimol Srisuparp; Nim V Subhedar; Krisa P Van Meurs; Merryn Voysey; Keith Barrington; Richard A Ehrenkranz; Neil Finer Journal: BMC Pediatr Date: 2010-03-23 Impact factor: 2.125